Amicus Therapeutics Inc

NASDAQ:FOLD 4:00:00 PM EDT

13.04

+0.29 (+2.28%)

6:57:32 PM EDT: $13.50 +0.46 (+3.53%)

Market Cap (Intraday)	3.66B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$85.64 Million
Adjusted EPS	-$0.11

See more estimates

10-Day MA	$12.93
50-Day MA	$12.18
200-Day MA	$10.54

See more pivots

Amicus Therapeutics Inc Stock, NASDAQ:FOLD

3675 Market Street, Philadelphia, Pennsylvania 19104

United States of America

Phone: +1.215.921.7600

Number of Employees: 496

http://www.amicusrx.com

Description

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.